SG10201807631SA - Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions - Google Patents

Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Info

Publication number
SG10201807631SA
SG10201807631SA SG10201807631SA SG10201807631SA SG10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA
Authority
SG
Singapore
Prior art keywords
preparation
particles
liquid medium
cross flow
flow filtration
Prior art date
Application number
SG10201807631SA
Other languages
English (en)
Inventor
Hans Peter Niedermann
Heiko Bothe
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of SG10201807631SA publication Critical patent/SG10201807631SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
SG10201807631SA 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions SG10201807631SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431942P 2011-01-12 2011-01-12

Publications (1)

Publication Number Publication Date
SG10201807631SA true SG10201807631SA (en) 2018-10-30

Family

ID=45478323

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201807631SA SG10201807631SA (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
SG2013053764A SG191963A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013053764A SG191963A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Country Status (10)

Country Link
US (1) US9066864B2 (enExample)
EP (1) EP2663287A1 (enExample)
JP (1) JP5934719B2 (enExample)
CN (1) CN103347499B (enExample)
AU (1) AU2012206621B2 (enExample)
BR (1) BR112013016851B1 (enExample)
CA (1) CA2823972C (enExample)
MX (1) MX346749B (enExample)
SG (2) SG10201807631SA (enExample)
WO (1) WO2012095439A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478959B2 (ja) * 2016-09-07 2019-03-06 株式会社富士薬品 粒子含有組成物を製造するためのシステム及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790912B2 (ja) 1999-05-12 2011-10-12 メタボリックス,インコーポレイテッド ポリヒドロキシアルカノエートを精製するための方法
EP1225968B1 (en) 1999-09-17 2006-04-05 Alfa Laval Nakskov A/S A method and an apparatus for continuous cross-flow diafiltration
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
PL208585B1 (pl) * 2002-10-25 2011-05-31 Intervet Int Bv Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca cefquinom, sposób jej wytwarzania i zastosowanie cefquinomu
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂

Also Published As

Publication number Publication date
US9066864B2 (en) 2015-06-30
CA2823972C (en) 2019-05-28
MX346749B (es) 2017-03-29
WO2012095439A1 (en) 2012-07-19
SG191963A1 (en) 2013-08-30
JP2014502624A (ja) 2014-02-03
US20130281425A1 (en) 2013-10-24
EP2663287A1 (en) 2013-11-20
CN103347499B (zh) 2017-04-05
AU2012206621B2 (en) 2017-04-27
MX2013008118A (es) 2013-08-12
CN103347499A (zh) 2013-10-09
BR112013016851B1 (pt) 2021-08-31
CA2823972A1 (en) 2012-07-19
BR112013016851A2 (pt) 2016-10-04
AU2012206621A1 (en) 2013-07-04
JP5934719B2 (ja) 2016-06-15

Similar Documents

Publication Publication Date Title
SE0800304L (sv) Förfarande för framställning av etanol utifrån sockerartshaltig lösning/suspension medelst fermentering
WO2013064911A3 (en) Single use system for sterilely producing lipid-nucleic acid particles
WO2014100779A8 (en) Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2636511A4 (en) Modeling material for forming photoshaped article by ink-jet photoshaping method, support material for shape supporting during formation of photoshaped article by the photoshaping method, and process for producing photoshaped article by the photoshaping method
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
WO2012094425A3 (en) Biological methods for preparing adipic acid
PL2766682T3 (pl) Sposób, linia technologiczna i wykorzystanie linii technologicznej do wytwarzania cząstek liofilizowanych
NZ617308A (en) Aqueous process for preparing protein isolate and hydrolyzed protein from an oilseed
MX2014000753A (es) Procedimiento para producir antigeno viral y vacunas.
EP2764994A4 (en) COMPOSITE STRUCTURE, PRODUCTS THEREFOR AND METHOD FOR MANUFACTURING THE COMPOSITE STRUCTURE
PH12015500644B1 (en) Novel rig-i ligands and methods for producing them
EP2484673A3 (en) A process for the resolution of (R,S)-nicotine
HK1209726A1 (en) Protein kinase inhibitors
WO2012142302A3 (en) Biocatalytic process for preparing eslicarbazepine and analogs thereof
WO2013012808A3 (en) System for radiopharmaceutical preparation involving solid and liquid phase interactions
EA201270409A1 (ru) Способ производства промежуточных продуктов артемизинина
PL2797863T3 (pl) Sposób wytwarzania 1,3-butadienu
WO2012166822A3 (en) Method to produce polyhydroxyalkanoates from water-based feedstock streams
WO2015124683A3 (de) Filter, verwendung des filters und dessen herstellungsverfahren
WO2015101243A8 (zh) 雌性不育系的繁殖及杂交制种技术
MX346749B (es) Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco.
HK1204607A1 (en) Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds
MY169503A (en) Preparation method of new recombinant antibacterial polypeptide medicine
WO2013023254A8 (en) Method for the recovery of magnesium sulphate and production of magnesium oxide
JP2014502624A5 (enExample)